Ocugen, Inc. (NASDAQ: OCGN) is a Healthcare company (Biotechnology) with a market capitalization of $257M. The Maz Rating grades it against the other companies in its sector.
Ocugen, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.76, Ocugen, Inc. trades at 53.1x sales. Over the last twelve months it generated about $5M of revenue and a net loss of $68M. It runs a gross margin of 88.5%, an operating margin of -1444.5% and a net margin of -1367.6%. It shows return on equity of 644.0%, return on invested capital of -94.4% and a free cash flow yield of -24.9%. On the balance sheet: a debt-to-equity ratio of -5.01 and a current ratio of 0.77. Over the past 52 weeks the share price ranged from $0.69 to $2.73, with a beta of 2.04.
Ocugen, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 5 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.